We didn’t win but are honoured to be among the 10 finals of the Reboot Forum competition of medical innovations , with our initiative “UBTF between Science and Medicine“ following the idea of creating a unique model of an interdisciplinary roundtable of scientists and physicians concerning the UBTF mutation.
The people that reach the final stage of reboot competition 2018
These initiatives were chosen by ‘Reboot Forum’ because of their ability to lead to significant change among patients, their families or medical staffs, and to contribute to the sustainability of the healthcare system. They have won the annual ‘Health Initiative Of Year Contest’ and received an “Acceleration Package” that includes financial support, introduction to influencers & decision makers, professional advice and mentoring and broad professional and public exposure.
For further information please click Here
A rare mutation - Between Science and Medicine
In the framework of the goals of promoting research and development of drugs and innovative methods of treatment for the orphan disease - CONDBA, a first meeting took place on 9 March 2018, in Blavatnik Center for Drug Discovery.
In the meeting, there was a discussion regarding:
The scientific plan and collaboration between the two labs - in Blavatnik center and the Technion, scanning FDA approved drugs and cannabis derivate fractions on fibroblasts of children who suffer from the disease
A Genetic study in Haifa University on several patients DNA samples / Axoms. The aim is to test the possibility that several other mutations in other genes contribute to UBTF pathology.
A non-invasive technology such as the Neurosteer was suggested ( https://neurosteer.com/) that is a wearable device which can give a hint of ways to optimize some exercises for cognitive and motor maintenance. We will start soon.
A Study which will monitor circadian and yearly rhythms that will take place in TAU/Sagol. A disturbance may be a result of the disease or secondary to the change of lifestyle. In both cases, there is the damage to the quality of life and if it is so we can try to improve the situation
Analyzing the clinical data gathered from the other parents in Israel and around the world in order to have a better understanding of the pathophysiology and dynamics of the disease - Schneider hospital.
Dr. Anat Grienfeld
Prof. Miguel Weil
Dr. Talia kinnar MD
Prof. Gil Atzmon
Dr. Helit N. Rozen
Dr. YuvalLandau MD
Dr. Etty Ganelin MD
Prof. Dedi Meiri
Prof. NogaKronfeld -Schor
Prof. Miguel Weil
Neurobiology, Head of the Laboratory for Drug Research at the BLAVATNIK Center, Tel Aviv University / Sagol
Gil Atzmon, Ph.D. | Albert Einstein College of Medicine
The Laboratory of Genetics and Epigenetics of Aging and Longevity
Head of the Laboratory of Genetics and Epigenetics and Ageing, University of Haifa
Dr. Anat Grinfeld, PhD
Head of Research Unit, Department of Medical Imaging, Rambam
Prof. Noga Kronfeld Schor
Zoology, Head of the Laboratory of Ecological and Evolutionary Physiology Tel Aviv University / Sagol.
Prof. David (Dedi) Meiri
Laboratory of Cancer Biology and Cannabinoid Research
Dr. Helit Nabel Rozen
Genetics - Molecular research in cancer, advanced microscopic use. The Technion
Dr. Talia Kinnar MD Family Medicine
Dr. Yuval Landau MD Neurology - metabolism Schneider Hospital
Dr. Ganelin Etty MD Neuroimmunology Schneider Hospital
Expressed their willingness to cooperate in the future:
Dr. Pavel Goldstein - Colorado University / Cognitive and Affective Neuroscience Laboratory
Dr. Rami Reshef - Head of the Department of Evolutionary Biology, University of Haifa
Prof. Gidi Rechavi - Director of the Sheba Center for Cancer Research Sheba Hospital
Dr. Oded Rechavi - Neurobiology / Genetics Tel Aviv University / Sagol
23.3.18 - Prof Nathan Intrator - Computer science / Tel Aviv University / Sagol
Will contribute with the new technology of neurosteer (https://neurosteer.com)